Articles from Bayer

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions underway for key growth drivers darolutamide, finerenone, and elinzanetant.

Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI). All QUANTI studies investigated gadoquatrane at a gadolinium dose of 0.04 mmol Gd/kg body weight which represents a gadolinium dose reduction of 60 percent compared to the macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. Gadoquatrane successfully met the primary and main secondary endpoints of all QUANTI studies.

Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone) for the treatment of patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%.

Bayer today announced positive topline results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer. Elinzanetant successfully met the primary endpoints of the study demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo. The study also achieved all secondary endpoints demonstrating reductions in severity of VMS at week 4 and 12, VMS frequency reduction at week 1 as well as maintaining the effects over the study period. Elinzanetant also showed improvements of sleep disturbances and menopause-related quality of life at week 12 compared to placebo. The safety profile over 52 weeks observed in the OASIS 4 study is generally consistent with previously conducted studies and published data1,2,3 on elinzanetant in postmenopausal women with VMS.

The Federal Court of Australia brought an end to the last Roundup™ case in Australia, closing all pending injury litigation there. The Court granted the plaintiffs’ request to discontinue the Fenton class action against Monsanto involving allegations related to Roundup™. This action follows the company’s earlier victory in the McNickle case in the same court.

Bayer announced the successful completion of its fall employee engagement campaign with America’s Grow-a-Row (AGAR), a New Jersey-based, nonprofit farm where approximately 300 employees harvested 156,000 pounds of corn and turnips. This four-day effort hand-collected the produce, which was donated to local food banks, resulting in an estimated 628,000 meals to families in need.

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will showcase these advancements at the 2024 Radiological Society of North America (RSNA) Annual Meeting taking place from December 1-5, 2024, in Chicago.

Bayer announced today an expanded approach to its programs that sequester carbon and reduce emissions for companies along the food value chain through regenerative agriculture practices. In addition to helping to reduce these companies’ Scope 3 emissions, “Project Enhanced S3” will include data on benefits from regenerative agriculture practices, such as soil health, more efficient water usage, enhanced biodiversity, and economic support for farmers. Project Enhanced S3 is currently in development, with the goal of helping companies quantify, measure and report the added value of carbon projects taking place on farms in their supply chain, along with a portal to enable them to more easily access insights.

Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA® (finerenone) in heart failure (HF) patients with a left ventricular ejection fraction (LVEF) of ≥40%, in a Featured Science session at the American Heart Association (AHA) Scientific Sessions 2024, taking place in Chicago, IL, from November 16-18, 2024.

Bayer announced today 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD® Centargo CT Injection System, an innovative multi-patient injector that drives workflow efficiency with design features that integrate with Bayer’s portfolio of products, especially in high-volume CT suites. Bayer’s MEDRAD® Centargo CT Injection System delivers value for radiology departments as the US faces a shortage of radiology technologists coupled with a rising demand for medical imaging.

Bayer has launched a first-of-its-kind in the healthcare industry, polyethylene terephthalate (PET) blister packaging on its renowned brand, Aleve. Realized in partnership with pharma packaging specialist Liveo Research, this innovative solution reduces the carbon footprint of this packaging by 38%1 and marks a stride in environmental stewardship by eliminating the use of polyvinyl chloride (PVC). Blister packaging, widely used in over-the-counter products, has long posed a challenge for environmental sustainability due to its multilayer composition of plastic and aluminum, which makes it hard to sort and recycle. Launching first in the Netherlands, in the coming years, the company has the ambition to replace all of its blister packaging with more sustainable alternatives.

Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for the investigational compound elinzanetant seeking approval for the treatment of moderate-to-severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause.

Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that they have entered into a collaboration, under an option and exclusive license agreement, to develop and commercialize a small molecule oncology program based on MOMA’s proprietary KNOMATIC™ platform. Under the agreement, Bayer will be responsible for completing further preclinical, development and commercial activities.

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG today announced positive 24-month data from exPDite, a Phase 1 clinical trial of bemdaneprocel, an investigational cell therapy for the treatment of Parkinson's disease.

Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

In honor of World Dense Breast Day on September 25, Bayer announced today a new study, published in Patient Preference and Adherence, evaluating awareness and knowledge gaps of breast cancer risk factors (BCRFs) among women with and without high breast density (HBD). The study, a web-based survey, found only 39 percent were familiar with the concept of HBD in the context of breast cancer, and 31 percent were aware of HBD as a Breast Cancer Risk Factor (BCRF). Three thousand women were surveyed from six different countries – the United States, Germany, Italy, South Korea, Brazil and Mexico (500 from each country). The survey was supported by Bayer and conducted with Trinity Life Sciences in the U.S., University Medical Center Utrecht in the Netherlands and University Medical School of Saarland in Germany.1

Bayer, UPMC Magee-Womens Hospital and Pennsylvania State Senator Kim Ward (R-Westmoreland County) are collaborating to address the health access gaps that disproportionally impact women in rural communities, specifically those associated with breast health care. The collaboration will provide information on health and food insecurities and will bring mammography breast cancer screenings to those in rural and underserved communities.

Results from the investigational pivotal Phase III ARANOTE trial demonstrated that NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant and clinically meaningful improvement in radiological progression-free survival (rPFS) compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC).1 The results were presented today as a late-breaking oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain and published simultaneously in The Journal of Clinical Oncology.

After 120 years, Bayer 04 Leverkusen won its first Bundesliga earlier this year and now, the champions are taking the celebration on the road this month as the club embarks on its first-ever trophy tour in the U.S. Each year, the Bundesliga, Germany's top professional soccer league, awards the Meisterschale trophy to the winners of the season.

Itching for allergy relief this fall? So are residents of Wichita, Kansas, the No. 1 allergy capital in the United States, according to the Asthma and Allergy Foundation of America (AAFA). This September, Claritin®, the #1 doctor-recommended non-drowsy oral allergy OTC brand from Bayer, is aiming to take the “itch” out of Wichita and bring relief to its residents with its newest innovation, Claritin® Liquid. The new product is the only allergy treatment to offer the proven allergy relief of non-drowsy Claritin® in an instantly soothing Cooling Honey Flavored Liquid, providing 24-hour indoor and outdoor allergy relief of the most irritating allergy symptoms, including itchy throat.

Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding to the positive results of the OASIS 1 and 2 studies. These data will be presented at the 2024 annual meeting of The Menopause Society (TMS) taking place from September 10-14, in Chicago, IL, USA.

Bayer announced encouraging results from the expansion part of the ongoing Phase I/II SOHO-01 study evaluating the safety and preliminary efficacy of BAY 2927088 in advanced HER2-mutant non-small cell lung cancer (NSCLC). Data were presented during the Presidential Symposium at the IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place in San Diego, United States, from September 7-10, 2024.

Bayer will present new oncology data, including a late-breaking, comprehensive analysis from the Phase III ARANOTE trial investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024.

Bayer will present detailed results from the Phase III long-term study OASIS 3, evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo, at the upcoming annual meeting of The Menopause Society (TMS) which takes place from September 10 – 14, in Chicago, IL, United States. Additional elinzanetant presentations include pooled efficacy results from the pivotal Phase III studies OASIS 1 and 2, which will be presented for the first time during the meeting.

Detailed results from the Phase III FINEARTS-HF trial presented today at the European Society of Cardiology (ESC) Congress 2024 during a late-breaking Hot Line session and simultaneously published in the New England Journal of Medicine showed that KERENDIA® (finerenone) achieved a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as either an unplanned hospitalization for HF or an urgent HF visit, by 16% (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007) in patients with HF and a LVEF ≥40% (left ventricular ejection fraction) compared to placebo in addition to a patients’ prescribed treatment regimen.1

Bayer will present late-breaking Phase III data from the FINEARTS-HF trial investigating KERENDIA® (finerenone) in patients with heart failure (HF) and LVEF ≥40% (left ventricular ejection fraction),1 at the European Society of Cardiology (ESC) Congress 2024. Additionally, the company will present results from FINE-HEART, an integrated, pooled, participant-level analysis across three pivotal Phase III clinical trials with finerenone—FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD—that explored cardio-kidney outcomes in patients with HF with LVEF ≥40%, and/or chronic kidney disease (CKD) and type 2 diabetes (T2D).2

Bayer announced today that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of investigational agent BAY 2927088 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC), whose tumors have activating HER2 mutations.

Bayer and NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, today announced that they have entered into a collaboration and license agreement to develop small molecule therapeutics targeting lncRNAs in oncology. lncRNAs represent a vast class of therapeutic targets that recruit RNA-binding proteins (RBPs) to drive pathological processes across diseases. Disrupting lncRNA-RBP interactions with small molecules represents an innovative approach to develop a new class of therapeutic agents.

Bayer today unveiled FieldView Drive 2.0, a small plug-and-play device that farmers can use to connect, monitor and record activities across different farm equipment types and brands. An upgrade over the previous generation, FieldView Drive 2.0 provides more processing power, data storage, and in-field connection stability to improve how farmers connect with digital solutions and gather data during planting, spraying, and harvest activities.

Data published in The Journal of the American Medical Association (JAMA) from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant, has shown consistent results across both studies and are in line with the Phase II SWITCH study1. This data reinforces the strong evidence of efficacy and safety of the compound. Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, administered orally once daily.

Bayer announced today the start of ALPINE-1 study, a Phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The results of this study have the potential to provide evidence of the sGC activator as a viable treatment option for cardiovascular diseases.

As Radiology administrators from around the US gather for the annual AHRA (American Healthcare Radiology Administrators) conference, Bayer is announcing an exploratory collaboration with Alara Imaging, Inc.

Bayer announced today that FINEARTS-HF met its primary endpoint,1 achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40%2 (left ventricular ejection fraction), a measurement that indicates how much blood the left ventricle of the heart pumps with each beat.4 In the FINEARTS-HF trial, no new safety signals were identified compared with those seen in previous studies with the compound.1

Bayer today announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause. The submission is based on the positive results from the Phase III OASIS 1, 2 and 3 studies.

The Phase III ARANOTE trial, investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of radiological progression-free survival (rPFS). NUBEQA plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.

Bayer and Kroger joined forces with country music star Luke Bryan and Feeding America to bring healthy food to more families who need it. According to Feeding America’s latest data, more than 44 million people in the United States are food insecure1, including a nearly 30% increase – more than 10 million – compared to the previous year.

One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, announced today the launch of One A Day® Age Factor™ Cell Defense, a dietary supplement that helps defend against cellular aging from the inside – where aging begins.

As experts from around the globe gather at the annual Society for Informatics in Medicine (SIIM) conference, Bayer and Rad AI are announcing a collaboration to bring Rad AI’s cutting edge AI radiology operational solutions to Calantic ™ Digital Solution customers.

The start of summer means the kickoff of the ultimate dating season, but a survey commissioned by Alka-Seltzer®, the #1 effervescent antacid brand from Bayer, uncovered potential trouble for love seekers: 1 in 2 (50%) Americans surveyed have canceled a social engagement like a date due to digestive issues such as heartburn or upset stomach. Today, the brand introduces the ultimate wingman – NEW Alka-Seltzer Fizzy Melts – ensuring any unwanted occasional heartburn doesn’t get in the way of romance.

Despite significant prevalence among Americans, there are no federal government kidney screening recommendations for chronic kidney disease (CKD), which could increase testing and diagnosis and potentially allow for earlier treatment intervention. Today, four leading kidney patient and professional organizations, Platinum recording artist and kidney health advocate Freeway (Leslie Pridgen), and the Congressional Kidney Caucus took a powerful step to change that.

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause compared to placebo. In addition, elinzanetant met its key secondary endpoints showing a statistically significant reduction in the frequency of VMS from baseline to week 1 and improved sleep disturbances and menopause related quality of life compared to placebo. These data will be presented at the 2024 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting taking place from May 17 – 19 in San Francisco, CA, USA.

Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024. The breadth of new data in different tumor types underscores Bayer’s ambition to deliver innovative and effective oncological therapies in areas with the highest unmet medical needs.

Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The investigational candidate, labeled with actinium-225 and comprising a novel PSMA (prostate-specific membrane antigen) -targeting small molecule with a customized albumin-binding moiety, is designed to potentially improve therapeutic efficacy and reduce side effects in normal organs such as salivary glands. The dose-escalation study (NCT06217822) will evaluate the safety, tolerability and efficacy of 225Ac-PSMA-Trillium in patients with advanced metastatic castration resistant prostate cancer (mCRPC).

The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone1, were presented today as a Late-Breaking Science Session at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC) in Lisbon.

One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, has launched a new campaign to address the prevalence of wellness fads and misinformation and remind consumers to trust science when it comes to their wellness journey. The social campaign #WellnessConfessionals also gives people a platform to divulge the wellness fads they have been falling for.

Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind, placebo-controlled, multicenter, event-driven Phase III study is investigating the efficacy (including CV death and total HF events) and safety of finerenone compared to placebo in patients suffering from symptomatic HF with an ejection fraction of ≥40% (HFmrEF/HFpEF), at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), taking place May 11-14, 2024 in Lisbon, Portugal.

WomenHeart: The National Coalition for Women with Heart Disease, in collaboration with Bayer, is proud to announce the launch of the Understanding Her Heart: Women and Cardiovascular Disease initiative. This groundbreaking partnership aims to bolster awareness of heart disease risk factors among women, enhance accessibility to vital heart health information and resources, and mobilize women leaders to champion heart health education in their local communities and nationwide.

Fifty percent of people with periods reported they did not know what was happening to their body when they first experienced period symptoms and only around 40% of respondents could name the four phases of the menstrual cycle.1 On average, people with periods spend more than half of their lifetime experiencing periods yet many of them do not fully understand what is happening to their bodies. Today, Midol® and nonprofit partner PERIOD. launched the PeriodTalk with Midol campaign to help bring further awareness to the gaps in period education and dialogue to ultimately mend the discrepancies.

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting. ACOG takes place from May 17 – 19, in San Francisco, CA, United States.

After more than 60 years of researching the power of plants in Germany, Bayer Consumer Health is introducing Iberogast™, a plant-based digestive relief product, to the United States. Formulated with a clinically proven, proprietary six-herb blend, Iberogast harnesses the power of nature to provide dual-action relief for those who experience occasional digestive symptoms by helping to relieve stomach upsets and restore digestive function.*

Bayer and Hologic, Inc. (Nasdaq: HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada.

Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will further develop its innovation platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud’s technology, including its generative AI (gen AI) tools. The collaboration aims to help organizations overcome many of the challenges to building scalable and compliant AI-powered medical imaging software products using leading data security capabilities and accelerate the development of potentially groundbreaking and impactful solutions that ultimately benefit patients.

Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May.

Bayer today announced Sue Ann Pentecost as the new Vice President, Head of Pharmaceuticals Communications in the United States. She will report directly to Beth Roden, Senior Vice President, Head of Communications for Bayer U.S., and Head of Communications Bayer Consumer Health NA. Pentecost succeeds Lori Moore, who is retiring at the end of May.

Aleve®, a marquee pain relief product from Bayer indicated for minor pain, in partnership with Mothers Against Prescription Drug Abuse (MAPDA), today launched “The Painful Truth,” a campaign developed to encourage consumers to explore, with their doctors, pain relief options such as over-the-counter (OTC) products before taking opioids, when appropriate.

Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer’s growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

Bayer’s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused.

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo. In this study, elinzanetant successfully met the primary endpoint demonstrating statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 12 compared to placebo. The long-term safety profile observed over 52 weeks in the OASIS 3 study is overall consistent with previously conducted studies and published data1,2 on elinzanetant.

Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia.

Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR.1,2

Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high medical relevance.

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).

A new solar array installation at Bayer’s vegetable research and development site in Woodland, CA will provide 70% of the site’s electrical energy demand.

Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will serve on the Pharmaceuticals Executive Committee and be based in Berlin, Germany. Gerd Krueger, who has led the Radiology unit for the past eight years, will work closely with him on a smooth transition before retiring from Bayer after more than forty years of service at the end of March 2024.

MiraLAX®, the #1 brand choice for effective, gentle, occasional constipation relief from Bayer, today released the findings of a brand-commissioned survey which found women to be more than twice as likely as men to be pooping less than three times a week. Stress may be a contributing factor to this constipation; in fact, the survey, which was conducted among 2,000 Americans aged 27-42, found a staggering 85% of millennial women report routinely having stress on their minds. This high frequency of stress and constipation that American women are facing is what MiraLAX has coined “The Gut Gap™.” With 9 in 10 millennial women reporting that stress impacts their gut, MiraLAX is committed to exposing – and closing – The Gut Gap and helping women get the relief they need.

Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California. These presentations underscore Bayer’s commitment to advance prostate cancer care.

Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled into NIRVANA, an exploratory Phase II study to evaluate the efficacy and safety of elinzanetant in women with sleep disturbances associated with menopause (SDM).

Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints in both studies demonstrating statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) from baseline to week 4 and 12 compared to placebo.

On Friday, December 22, a jury reached a defense verdict in the Jones Roundup™ product liability trial before Judge Patrick Palacios in the Superior Court of California, San Benito County, and the Company issued the following statement.

Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

For the sixth consecutive year, Bayer U.S. received a score of 100 on the Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality.

Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.

Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies’ shared ambition to transform self-care through personalized solutions.

Bayer announced today the publication of a novel health economic model in the Journal of Medical Economics, funded by Bayer, analyzing cost effectiveness and infrastructural capacity of supplemental imaging modalities for women with dense breasts at average or intermediate risk of breast cancer.